ArticleQuantitative imaging in medicine and surgery2026
Acute susceptibility changes of deep gray matter nuclei to gadobutrol: a prospective longitudinal study using quantitative susceptibility mapping.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gadolinium-based contrast agents (GBCAs) are associated with gadolinium deposition in the brain. Quantitative susceptibility mapping (QSM) enables sensitive quantification of paramagnetic substances. However, the acute and cumulative effects of macrocyclic GBCAs on deep gray matter nuclei remain incompletely understood, with prior evidence largely based on cross-sectional studies lacking robust longitudinal data within the same individuals. Therefore, this prospective longitudinal study aimed to investigate acute susceptibility changes in deep gray matter nuclei following gadobutrol administration and to evaluate the sensitivity of QSM in detecting subtle susceptibility changes in these regions associated with cumulative use. Methods: In this prospective longitudinal study, 72 patients (mean age 59±10 years, 39 males/33 females) underwent multi-parametric magnetic resonance imaging (MRI) at 3-Tesla, including QSM, T1 mapping, and T2* mapping, both before and after gadobutrol administration. QSM values were measured across 14 deep gray matter nuclei. The number of prior GBCA administrations and clinical variables (age, sex, tumor type, radiotherapy/chemotherapy history) were recorded. Statistical analyses included paired Results: Significant post-injection susceptibility changes were observed in specific deep gray matter nuclei: increases in the left amygdala (pre: -15.61 ppb, post: -14.42 ppb, Cohen's d =0.20) and right hippocampus (pre: 2.44 ppb, post: 4.41 ppm, Cohen's d =0.48), and decreases in the left hippocampus (pre: 1.64 ppb, post: 0.87 ppb, Cohen's d =-0.19), bilateral putamen (left: pre: 48.55 ppb, post: 47.13 ppb, Cohen's d =-0.12; right: pre: 22.45 ppb, post: 21.56 ppb, Cohen'd =-0.09), and bilateral globus pallidus (pallidum) (left: pre: 35.04 ppb, post: 30.71 ppb, Cohen's d =-0.21; right: pre: 98.99 ppb, post: 93.05 ppb, Cohen's d =-0.20) (all P<0.05). A negative correlation was found between ΔQSM and ΔT2* in the left pallidum (R=-0.35, P<0.001) and the right pallidum (R=-0.27, P=0.003); in the right putamen, ΔQSM and ΔT2* exhibited a significant negative correlation (R=-0.25, P=0.005). However, in the right hippocampus, ΔQSM and ΔT2* exhibited a significant positive correlation (R=0.21, P=0.021). A significant difference was found in the right hippocampus based on lesion presence (P<0.001), but there was no significant effect on the left hippocampus (P=0.51). The number of prior gadobutrol injections was positively associated with susceptibility in the left amygdala [β =0.88; 95% confidence interval (CI): 0.06, 1.73; P=0.04]. Conclusions: Gadobutrol administration induces spatially heterogeneous susceptibility changes in deep gray matter nuclei, demonstrating acute susceptibility changes. QSM detected changes not significantly correlated with ΔT1, supporting its potential advantage over traditional T1-weighted imaging (T1WI) for detecting gadolinium deposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.